EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Angion Biomedica's enterprise value is $272.22 Mil.
Angion Biomedica's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $0.65 Mil. Therefore, Angion Biomedica's EV-to-Revenue for today is 416.87.
The historical rank and industry rank for Angion Biomedica's EV-to-Revenue or its related term are showing as below:
ANGN's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.03 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-17), Angion Biomedica's stock price is $10.00.
Angion Biomedica's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.02. Therefore, Angion Biomedica's PS Ratio for today is 454.55.
Angion Biomedica EV-to-Revenue Historical Data
The historical data trend for Angion Biomedica's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Angion Biomedica's EV-to-Revenue
For the Biotechnology subindustry, Angion Biomedica's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angion Biomedica's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Angion Biomedica's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Angion Biomedica's EV-to-Revenue falls into.
Angion Biomedica's current Enterprise Value is $272.22 Mil.
Angion Biomedica's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Angion Biomedica's share price for today is $10.00.
Angion Biomedica's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Angion Biomedica EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Angion Biomedica's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Angion Biomedica (Angion Biomedica) Business Description
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANGN has been successfully added to your 